Bruce Schnepp

Bruce brings over 20 years of experience developing viral vector technologies with an emphasis in adeno-associated virus vectors. Prior to Interius he served as Senior Director, Technology Development at Kriya Therapeutics, where he was responsible for vector design and assay development. Previously, Bruce held key scientific roles at Limelight Bio, where he led a team of scientists developing both AAV-mediated and non-viral therapeutics for genetic diseases, and with The Children’s Hospital of Philadelphia, where he was involved in the preclinical design and development of the first-in-human study that used a recombinant AAV vector to deliver a gene for a monoclonal antibody to block HIV infection.

Bruce received his Ph.D. in Molecular Genetics from The Ohio State University and completed his postdoctoral work at Nationwide Children’s Hospital in Columbus, Ohio. He received his undergraduate degree in Biology from Purdue University.